BOK Financial Private Wealth Inc. Has $1.30 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

BOK Financial Private Wealth Inc. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 13.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,618 shares of the medical research company’s stock after selling 1,004 shares during the quarter. BOK Financial Private Wealth Inc.’s holdings in IQVIA were worth $1,301,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. Raymond James Financial Inc. bought a new position in shares of IQVIA in the fourth quarter valued at $236,120,000. FMR LLC grew its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA in the third quarter valued at $147,683,000. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Barclays reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Performance

Shares of IQVIA stock opened at $191.69 on Friday. The company has a market cap of $33.80 billion, a P/E ratio of 25.56, a PEG ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a 50-day moving average price of $197.79 and a two-hundred day moving average price of $212.87. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.72.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.